nuvaring and Body-Weight

To assess clinical experience with NuvaRing in daily practice in Switzerland, including a large subgroup of young women (aged < or = 22 years).. Open, prospective, multicentre, observational clinical experience study to investigate cycle control, acceptability and usage of NuvaRing.. Altogether, 2642 women participated in the programme and were included in the analysis, of which 658 were aged < or = 22 years (25% of the total group). A total of 744 women (28% of the total group) discontinued NuvaRing use; the main reason was adverse events (11% of all users). In younger women, there was a shift from moderate (-18%) and heavy (-45%) bleeding to mild bleeding (+71%) and dysmenorrhoea decreased by 60%, despite previous hormonal contraception use by 83% of women. Most women found ring insertion and removal to be straightforward (>95%), and were satisfied with its use (85%), primarily for the ring's once-a-month application (81%). Data were very similar for the total group. Cycle control and satisfaction were further improved with duration of treatment.. In daily practice, NuvaRing improved cycle control and was highly acceptable to women, including young women. Switchers from other hormonal methods also showed improved cycle control and high satisfaction.

Topics: Adolescent; Adult; Age Factors; Blood Pressure; Body Weight; Contraceptive Devices, Female; Desogestrel; Drug Combinations; Drug Delivery Systems; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Middle Aged; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Surveys and Questionnaires; Switzerland

The objective of this study was to compare cycle control, cycle-related characteristics and bodyweight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.. A randomized, multicentre, open-label trial in which 983 women were treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles.. Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent with NuvaRing than that with the COC (4.7-10.4%) and showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis. Intended bleeding was significantly better for all cycles with NuvaRing (55.2-68.5%) than that with the COC (35.6-56.6%) (P < 0.01). Changes from baseline in mean bodyweight and body composition parameters were relatively small for both groups with no notable between-group differences.. NuvaRing was associated with better cycle control than the COC, and there was no clinically relevant difference between the two groups in bodyweight.

Topics: Administration, Oral; Adult; Androstenes; Body Composition; Body Weight; Contraceptive Devices, Female; Contraceptives, Oral; Desogestrel; Drug Combinations; Ethinyl Estradiol; Humans; Intrauterine Devices; Menstrual Cycle; Patient Compliance